EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.

Adjusted earnings of 75 cents per share beat the Zacks Consensus Estimate of 65 cents. The company registered adjusted ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.